Search
for

    Learn

    5 / 801 results

      learn Stemoxydine

      chemical from L'Oreal that encourages hair to enter growth phase

      learn Bimatoprost

      a synthetic prostamide used to treat eyelashes also shows promise for stimulating hair growth on scalp

      learn Adenosine

      nucleoside used for hair regrowth stimulant properties

      learn Exosomes

      Microscopic delivery system that sends growth-promoting signals to hair follicles

      learn HMI-115

      much-hyped research compound targeting prolactin receptor in scalp

    Research

    5 / 1000+ results

    Community Join

    5 / 727 results

      community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

      in Research/Science  128 upvotes 2 years ago
      The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

      community The second shed has been brutal (4 months and ongoing)

      in Progress Pictures  44 upvotes 1 month ago
      The user experienced significant hair regrowth using topical finasteride and minoxidil but faced a prolonged shedding phase, leading them to increase the finasteride dose and add oral dutasteride. Despite concerns about shedding, they remain hopeful for regrowth and are supplementing with Vitamin D.

      community 2nd shed Update: Lost everything and still losing like crazy.

      in Update  176 upvotes 11 months ago
      The user experienced significant hair loss after initially successful treatment with minoxidil and finasteride, leading to a second shedding phase. They are considering switching to oral minoxidil for convenience and are advised to continue treatment despite the shedding, as regrowth is expected.

      community The story of RU58841/PSK3841

      in Research/Science 1 year ago
      RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.